

Sabino De Placido

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/37175/publications.pdf>

Version: 2024-02-01

207
papers

8,493
citations

44042

48
h-index

58549

82
g-index

212
all docs

212
docs citations

212
times ranked

13312
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 44-53. | 0.8 | 389 |
| 2 | Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 910-915. | 0.8 | 361 |
| 3 | Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 1. | 2.3 | 331 |
| 4 | Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 396-405. | 5.1 | 327 |
| 5 | Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet</i> , The, 2019, 393, 1440-1452. | 6.3 | 260 |
| 6 | Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2526-2534. | 1.9 | 194 |
| 7 | Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. <i>Breast Cancer Research</i> , 2011, 13, R67. | 2.2 | 188 |
| 8 | Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. <i>Cancer Research</i> , 2018, 78, 845-852. | 0.4 | 169 |
| 9 | Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2x2 factorial, randomised phase 3 trial. <i>Lancet</i> , The, 2015, 385, 1863-1872. | 6.3 | 164 |
| 10 | CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. <i>Frontiers in Oncology</i> , 2018, 8, 608. | 1.3 | 160 |
| 11 | First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2826-2835. | 0.8 | 152 |
| 12 | A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1113-1119. | 0.4 | 149 |
| 13 | Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4469-4474. | 0.8 | 131 |
| 14 | Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1360-1369. | 5.1 | 131 |
| 15 | Mechanisms of lapatinib resistance in HER2-driven breast cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 877-883. | 3.4 | 125 |
| 16 | Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study. <i>European Urology</i> , 2008, 54, 1089-1096. | 0.9 | 121 |
| 17 | Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 342-349. | 0.8 | 120 |
| 18 | 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 930-936. | 0.5 | 118 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. <i>Oncologist</i> , 2017, 22, 601-608. | 1.9 | 108 |
| 20 | Castration-Resistant Prostate Cancer. <i>Drugs</i> , 2010, 70, 983-1000. | 4.9 | 98 |
| 21 | Toll-like receptors and COVID-19: a two-faced story with an exciting ending. <i>Future Science OA</i> , 2020, 6, FSO605. | 0.9 | 96 |
| 22 | Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. <i>Breast Cancer Research</i> , 2014, 16, 440. | 2.2 | 94 |
| 23 | High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. <i>Breast</i> , 2014, 23, 69-75. | 0.9 | 92 |
| 24 | HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965. | 3.4 | 92 |
| 25 | Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. <i>Cancer Treatment Reviews</i> , 2019, 73, 73-83. | 3.4 | 88 |
| 26 | Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models. <i>Clinical Cancer Research</i> , 2013, 19, 138-147. | 3.2 | 87 |
| 27 | Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. <i>Cancer Treatment Reviews</i> , 2016, 46, 20-26. | 3.4 | 87 |
| 28 | Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer. <i>Cancer</i> , 2008, 112, 75-83. | 2.0 | 83 |
| 29 | Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. <i>BJU International</i> , 2011, 107, 234-239. | 1.3 | 82 |
| 30 | Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. <i>Cancer Treatment Reviews</i> , 2016, 50, 129-141. | 3.4 | 81 |
| 31 | A comprehensive outlook on intracerebral therapy of malignant gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 54-68. | 2.0 | 79 |
| 32 | Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU International</i> , 2012, 110, E661-6. | 1.3 | 76 |
| 33 | Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. <i>British Journal of Cancer</i> , 2017, 116, 1425-1435. | 2.9 | 76 |
| 34 | Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study. <i>Menopause</i> , 2016, 23, 1108-1113. | 0.8 | 75 |
| 35 | Paclitaxel in Pretreated Metastatic Penile Cancer: Final Results of a Phase 2 Study. <i>European Urology</i> , 2011, 60, 1280-1284. | 0.9 | 73 |
| 36 | Gene expression profiling in breast cancer: A clinical perspective. <i>Breast</i> , 2013, 22, 109-120. | 0.9 | 73 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1207-1213. | 1.1 | 67 |
| 38 | Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. <i>Menopause</i> , 2018, 25, 657-662. | 0.8 | 65 |
| 39 | Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485. | 5.1 | 59 |
| 40 | Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1089-1097. | 3.0 | 59 |
| 41 | Activity and Safety of Pegylated Liposomal Doxorubicin as First-Line Therapy in the Treatment of Non-Visceral Classic Kaposi's Sarcoma: A Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1578-1580. | 0.3 | 57 |
| 42 | Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. <i>Breast Cancer Research</i> , 2014, 16, R45. | 2.2 | 56 |
| 43 | Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. <i>Scientific Reports</i> , 2017, 7, 9388. | 1.6 | 56 |
| 44 | Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2010, 58, 906-911. | 0.9 | 55 |
| 45 | The emerging role of obesity, diet and lipid metabolism in prostate cancer. <i>Future Oncology</i> , 2017, 13, 285-293. | 1.1 | 55 |
| 46 | Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R60. | 2.2 | 54 |
| 47 | Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1345-1352. | 0.5 | 53 |
| 48 | Features of aggressive breast cancer. <i>Breast</i> , 2015, 24, 594-600. | 0.9 | 52 |
| 49 | Analysis of Differential miRNA Expression in Primary Tumor and Stroma of Colorectal Cancer Patients. <i>BioMed Research International</i> , 2014, 2014, 1-8. | 0.9 | 49 |
| 50 | Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. <i>Breast</i> , 2017, 31, 114-120. | 0.9 | 49 |
| 51 | Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment. <i>Cancer Treatment Reviews</i> , 2015, 41, 61-68. | 3.4 | 48 |
| 52 | Molecular Mechanism and Clinical Implications of Endocrine Therapy Resistance in Breast Cancer. <i>Oncology</i> , 2009, 77, 23-37. | 0.9 | 47 |
| 53 | Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e2117. | 0.4 | 45 |
| 54 | Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 421-432. | 1.4 | 45 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Imatinib mesylate in thymic epithelial malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 309-315. | 1.1 | 44 |
| 56 | Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy. <i>Medicine (United States)</i> , 2015, 94, e1861. | 0.4 | 43 |
| 57 | Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 149, 134-152. | 1.3 | 41 |
| 58 | Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1458-1467. | 5.1 | 41 |
| 59 | Biomarkers in localized prostate cancer. <i>Future Oncology</i> , 2016, 12, 399-411. | 1.1 | 39 |
| 60 | Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. <i>Molecular Cancer Research</i> , 2016, 14, 470-481. | 1.5 | 39 |
| 61 | Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , 2017, 71, 34-42. | 1.3 | 39 |
| 62 | Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 118, 178-186. | 1.3 | 39 |
| 63 | Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2013, 9, 889-897. | 1.1 | 38 |
| 64 | Approaches for targeting cancer stem cells drug resistance. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 1201-1212. | 2.5 | 38 |
| 65 | Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017, 82, 237-246. | 1.3 | 38 |
| 66 | Multiple treatment lines and prognosis in metastatic colorectal cancer patients. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 307-313. | 2.7 | 38 |
| 67 | Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 548-555.e3. | 0.9 | 37 |
| 68 | Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. <i>Oncotarget</i> , 2018, 9, 19861-19873. | 0.8 | 37 |
| 69 | Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. <i>Oncotarget</i> , 2015, 6, 26090-26103. | 0.8 | 37 |
| 70 | Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 960-972. | 1.1 | 36 |
| 71 | Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. <i>Journal of Translational Medicine</i> , 2013, 11, 161. | 1.8 | 36 |
| 72 | Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 534-541. | 2.0 | 35 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer. <i>Annals of Nuclear Medicine</i> , 2019, 33, 937-944. | 1.2 | 35 |
| 74 | First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103198. | 2.0 | 35 |
| 75 | New Perspectives in the Therapy of Castration Resistant Prostate Cancer. <i>Current Drug Targets</i> , 2012, 13, 1676-1686. | 1.0 | 34 |
| 76 | Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. <i>BioMed Research International</i> , 2015, 2015, 1-14. | 0.9 | 34 |
| 77 | Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 127-132. | 1.1 | 33 |
| 78 | Clinical Characteristics of Metastatic Prostate Cancer Patients Infected with COVID-19 in South Italy. <i>Oncology</i> , 2020, 98, 743-747. | 0.9 | 33 |
| 79 | Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 408. | 1.7 | 32 |
| 80 | Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma. <i>Cancer</i> , 2008, 112, 1147-1152. | 2.0 | 31 |
| 81 | Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 451-458. | 1.1 | 31 |
| 82 | Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis. <i>BMC Cancer</i> , 2016, 16, 375. | 1.1 | 31 |
| 83 | Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology Focus</i> , 2018, 4, 874-879. | 1.6 | 30 |
| 84 | Combination of docetaxel and cetuximab for penile cancer. <i>Anti-Cancer Drugs</i> , 2012, 23, 573-577. | 0.7 | 29 |
| 85 | Peg-filgrastim and cabazitaxel in prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2013, 24, 84-89. | 0.7 | 29 |
| 86 | Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. <i>Cancers</i> , 2019, 11, 981. | 1.7 | 29 |
| 87 | Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020, 5, e000853. | 2.0 | 29 |
| 88 | Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102992. | 2.0 | 28 |
| 89 | Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. <i>Breast</i> , 2018, 38, 86-91. | 0.9 | 27 |
| 90 | Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 401-409. | 1.1 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. <i>World Journal of Gastroenterology</i> , 2010, 16, 2526. | 1.4 | 27 |
| 92 | Predictive Factors of Complete Response to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer. <i>Oncology</i> , 2010, 78, 369-375. | 0.9 | 26 |
| 93 | Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial. <i>Frontiers in Pharmacology</i> , 2018, 9, 189. | 1.6 | 26 |
| 94 | Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 248-254. | 3.3 | 25 |
| 95 | Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1455-1461. | 1.1 | 24 |
| 96 | Urologic malignancies: advances in the analysis and interpretation of clinical findings. <i>Future Science OA</i> , 2021, 7, FSO674. | 0.9 | 24 |
| 97 | Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 171-180. | 2.0 | 23 |
| 98 | Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 147-154. | 1.1 | 23 |
| 99 | An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1491-1497. | 0.9 | 23 |
| 100 | An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 125. | 0.7 | 23 |
| 101 | Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2014, 10, 1353-1360. | 1.1 | 23 |
| 102 | Adjuvant Treatment for Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy: When, and for Whom?. <i>Clinical Colorectal Cancer</i> , 2014, 13, 185-191. | 1.0 | 23 |
| 103 | Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or) Tj ETQq1 1 0.784314 rgBT /Over 487. | 1.6 | 23 |
| 104 | <p>Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2989-2997. | 1.0 | 23 |
| 105 | Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019, 24, 385-393. | 1.9 | 23 |
| 106 | The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1387-1401. | 1.4 | 22 |
| 107 | PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom. <i>Breast Care</i> , 2017, 12, 290-294. | 0.8 | 21 |
| 108 | Fast Detection of a BRCA2 Large Genomic Duplication by Next Generation Sequencing as a Single Procedure: A Case Report. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2487. | 1.8 | 20 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Definition of High-Risk Early Hormone-Positive HER2 ⁺ Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898. | 1.7 | 20 |
| 110 | Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients. <i>Cancer</i> , 2009, 115, 517-523. | 2.0 | 19 |
| 111 | Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. <i>BMC Cancer</i> , 2013, 13, 164. | 1.1 | 19 |
| 112 | FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma. <i>Anti-Cancer Drugs</i> , 2013, 24, 980-985. | 0.7 | 19 |
| 113 | The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer. , 2016, 4, . | | 18 |
| 114 | Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1259. | 1.7 | 18 |
| 115 | Assessment of Total, PTEN ⁺ , and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e286-e298. | 0.9 | 18 |
| 116 | Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports. <i>World Journal of Clinical Cases</i> , 2014, 2, 228. | 0.3 | 18 |
| 117 | Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study. <i>Oncotarget</i> , 2017, 8, 115709-115717. | 0.8 | 18 |
| 118 | Targeting fibroblast growth factor receptor pathway in breast cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 452-456. | 1.1 | 17 |
| 119 | Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. <i>Future Oncology</i> , 2015, 11, 3091-3098. | 1.1 | 17 |
| 120 | Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1458. | 1.7 | 17 |
| 121 | Third-Line Chemotherapy for Metastatic Urothelial Cancer. <i>Medicine (United States)</i> , 2015, 94, e2297. | 0.4 | 16 |
| 122 | It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature. <i>BMC Cancer</i> , 2018, 18, 146. | 1.1 | 16 |
| 123 | Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study. <i>Oncologist</i> , 2021, 26, e1854-e1861. | 1.9 | 16 |
| 124 | Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , 2011, 97, 690-2. | 0.6 | 15 |
| 125 | Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. <i>Oncotarget</i> , 2016, 7, 40073-40084. | 0.8 | 15 |
| 126 | EGFR mutational status in penile cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 501-505. | 1.5 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|----------|-----------|
| 127 | Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. <i>Medicine (United States)</i> , 2019, 98, e16711. | 0.784314 | 14 |
| 128 | Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 669-678. | 1.2 | 14 |
| 129 | Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. <i>Breast</i> , 2013, 22, 470-475. | 0.9 | 13 |
| 130 | Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. <i>Journal of Cancer</i> , 2020, 8, e001154. | | 13 |
| 131 | Combined Imaging With 18F-FDG-PET/CT and 111In-Labeled Octreotide SPECT for Evaluation of Thymic Epithelial Tumors. <i>Clinical Nuclear Medicine</i> , 2013, 38, 354-358. | 0.7 | 12 |
| 132 | Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study. <i>Clinical Breast Cancer</i> , 2017, 17, 559-563. | 1.1 | 12 |
| 133 | Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy). <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 100-107. | 0.784314 | 12 |
| 134 | Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421. | 1.7 | 12 |
| 135 | Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. <i>Anti-Cancer Drugs</i> , 2009, 20, 277-280. | 0.7 | 11 |
| 136 | Heterogeneity of SSTR2 Expression Assessed by ⁶⁸ Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1509-1514. | 2.8 | 11 |
| 137 | In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 3091-3100. | 1.9 | 10 |
| 138 | Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. <i>Oncologist</i> , 2020, 25, e1509-e1515. | 1.9 | 10 |
| 139 | EMPACT Syndrome Associated with Phenobarbital. <i>Dermatitis</i> , 2013, 24, 37-39. | 0.8 | 9 |
| 140 | Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. <i>Gynecologic Oncology</i> , 2019, 154, 83-88. | 0.6 | 9 |
| 141 | Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era. <i>ESMO Open</i> , 2020, 5, e000885. | 2.0 | 9 |
| 142 | A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103191. | 2.0 | 9 |
| 143 | Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103649. | 2.0 | 9 |
| 144 | Prevalence of Sarcopenia in Women with Breast Cancer. <i>Nutrients</i> , 2022, 14, 1839. | 1.7 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Nab-paclitaxel for the management of triple-negative metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 117-122. | 0.7 | 8 |
| 146 | High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients. <i>Medicine (United States)</i> , 2018, 97, e11254. | 0.4 | 8 |
| 147 | Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study. <i>World Journal of Clinical Oncology</i> , 2021, 12, 355-366. | 0.9 | 8 |
| 148 | Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation. <i>Anti-Cancer Drugs</i> , 2015, 26, 236-239. | 0.7 | 7 |
| 149 | FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094797. | 1.4 | 7 |
| 150 | Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. <i>Oncotarget</i> , 2020, 11, 2083-2091. | 0.8 | 7 |
| 151 | Is There a Standard Chemotherapeutic Regimen for Hormone-Refractory Prostate Cancer? Present and Future Approaches in the Management of the Disease. <i>Tumori</i> , 2003, 89, 349-360. | 0.6 | 6 |
| 152 | Time required to start multicentre clinical trials within the Italian Medicine Agency programme of support for independent research. <i>Journal of Medical Ethics</i> , 2015, 41, 799-803. | 1.0 | 6 |
| 153 | Epigenetic Silencing of <i>THY1</i> Tracks the Acquisition of the Notch-EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells. <i>Molecular Cancer Research</i> , 2019, 17, 628-641. | 1.5 | 6 |
| 154 | Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096872. | 1.4 | 6 |
| 155 | EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 83. | 2.2 | 6 |
| 156 | Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. <i>BMC Cancer</i> , 2020, 20, 232. | 1.1 | 6 |
| 157 | Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020, 136, 43-51. | 1.3 | 6 |
| 158 | Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989985. | 1.4 | 6 |
| 159 | Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 82. | 2.3 | 6 |
| 160 | Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy. <i>Frontiers in Oncology</i> , 2021, 11, 754108. | 1.3 | 6 |
| 161 | The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Cancer</i> , 2017, 8, 2663-2668. | 1.2 | 5 |
| 162 | A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA. <i>Frontiers in Oncology</i> , 2020, 10, 602153. | 1.3 | 5 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Long term deficiency of vitamin D in germ cell testicular cancer survivors. <i>Oncotarget</i> , 2018, 9, 21078-21085. | 0.8 | 5 |
| 164 | Breast cancer subtypes according to body mass index and insulin resistance.. <i>Journal of Clinical Oncology</i> , 2014, 32, 571-571. | 0.8 | 5 |
| 165 | Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?. <i>Journal of Neuro-Oncology</i> , 2010, 100, 311-319. | 1.4 | 4 |
| 166 | PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. <i>Medicine (United States)</i> , 2017, 96, e6817. | 0.4 | 4 |
| 167 | Clinical features and psychological aspects of the decision-making process in stage I testicular germ cell tumors. <i>Future Oncology</i> , 2018, 14, 1591-1599. | 1.1 | 4 |
| 168 | Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues. <i>Breast Journal</i> , 2019, 25, 1310-1311. | 0.4 | 4 |
| 169 | Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , 2020, 50, 56-63. | 0.9 | 4 |
| 170 | Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie. <i>Frontiers in Oncology</i> , 2021, 11, 602523. | 1.3 | 4 |
| 171 | Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 449-455. | 0.8 | 3 |
| 172 | Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. <i>Oncolmunology</i> , 2013, 2, e25123. | 2.1 | 3 |
| 173 | The evolving landscape in advanced penile cancer. <i>Future Science OA</i> , 2015, 1, FSO9. | 0.9 | 3 |
| 174 | Treatment options in HR+/HER2- advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?. <i>Future Oncology</i> , 2015, 11, 975-981. | 1.1 | 3 |
| 175 | Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study. <i>Cancers</i> , 2021, 13, 4939. | 1.7 | 3 |
| 176 | The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 832-836. | 0.9 | 3 |
| 177 | Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis. <i>Oncotarget</i> , 2017, 8, 112816-112824. | 0.8 | 3 |
| 178 | Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 611-617. | 0.8 | 2 |
| 179 | Non-small cell lung cancer: from targeted therapy to tailored therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1817-1819. | 0.9 | 2 |
| 180 | Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1079-1080. | 0.9 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Issues of banking breast cancer cells to generate mammospheres. <i>Cell and Tissue Banking</i> , 2013, 14, 153-158. | 0.5 | 2 |
| 182 | Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. <i>Tumori</i> , 2013, 99, e131-e133. | 0.6 | 2 |
| 183 | Cancer prevalence in the city of Naples: Contribution of the GP database analyses to the cancer registries network. <i>Molecular and Clinical Oncology</i> , 2013, 1, 726-732. | 0.4 | 2 |
| 184 | Using cumulative toxicity to identify the optimal second-line targeted therapy in patients with metastatic renal cell carcinoma: what's new?. <i>Future Oncology</i> , 2014, 10, 845-850. | 1.1 | 2 |
| 185 | Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer. <i>Medicine (United States)</i> , 2016, 95, e2754. | 0.4 | 2 |
| 186 | Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2016, 14, 18. | 0.6 | 2 |
| 187 | Discordance in RAS Mutations between Primary Colon Tumor and Metastases: A Real Event or a Matter of Methodology?. <i>International Journal of Biological Markers</i> , 2017, 32, 474-477. | 0.7 | 2 |
| 188 | Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma. <i>Anti-Cancer Drugs</i> , 2019, 30, 959-963. | 0.7 | 2 |
| 189 | Triple-negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12549-e12549. | 0.8 | 2 |
| 190 | BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report. <i>Genes</i> , 2021, 12, 1917. | 1.0 | 2 |
| 191 | Combination of Cytotoxic Drugs for Patients with HER2-Negative Metastatic Breast Cancer. <i>Combination Products in Therapy</i> , 2013, 3, 25-37. | 1.1 | 1 |
| 192 | Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations. <i>Future Oncology</i> , 2015, 11, 2251-2254. | 1.1 | 1 |
| 193 | Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13509-e13509. | 0.8 | 1 |
| 194 | Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series. <i>Molecular and Clinical Oncology</i> , 2020, 12, 456-460. | 0.4 | 1 |
| 195 | Anti-EGFR target therapy in advanced thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8567-8567. | 0.8 | 1 |
| 196 | Evaluation of a Four-Gene Panel for Hereditary Cancer Risk Assessment. <i>Genes</i> , 2022, 13, 682. | 1.0 | 1 |
| 197 | Immunological signature of patients with thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8589-8589. | 0.8 | 1 |
| 198 | Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study. <i>Oncologist</i> , 2013, 18, 924-925. | 1.9 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO). , 2016, 4, . | | 0 |
| 200 | Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. Clinical Colorectal Cancer, 2020, 19, 270-276. | 1.0 | 0 |
| 201 | Pneumonitis in patients with thymoma and Good's syndrome.. Journal of Clinical Oncology, 2021, 39, e20595-e20595. | 0.8 | 0 |
| 202 | Bevacizumab maintenance in metastatic colorectal cancer: How long?. World Journal of Clinical Cases, 2014, 2, 717. | 0.3 | 0 |
| 203 | Risk factors for cancer-related venous thromboembolism in ambulatory patients.. Journal of Clinical Oncology, 2014, 32, e20625-e20625. | 0.8 | 0 |
| 204 | Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.. Journal of Clinical Oncology, 2019, 37, e12528-e12528. | 0.8 | 0 |
| 205 | Abstract P3-09-03: Single nucleotide polymorphisms of aromatase gene (<i>CYP19A1</i>) and toxicity of adjuvant aromatase inhibitors: A translational, prospective study. Cancer Research, 2022, 82, P3-09-03-P3-09-03. | 0.4 | 0 |
| 206 | FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study. Future Oncology, 0, , . | 1.1 | 0 |
| 207 | Impaired seroconversion after SARS-COV-2 mRNA vaccine in patients with thymic epithelial tumors.. Journal of Clinical Oncology, 2022, 40, 8588-8588. | 0.8 | 0 |